Besides dopmaninergic D 2 blockers for positive symptoms, no other compound has demonstrated efficacy for any component of the illness
Angrisani L, Santonicola A, Iovino P, Palma R, Kow L, Prager G, et al
American College of Cardiology Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients with T2D and Atherosclerotic Cardiovascular Disease In 2018, the American College of Cardiology (ACC) published an expert consensus decision pathway on the use of novel therapies, namely GLP-1 RAs and SGLT-2 inhibitors, to reduce cardiovascular risk in patients with T2D
Aberrant astrocytes impair vascular reactivity in Huntington disease
The evidence base for DSIP in humans is limited
Women are more likely to suffer from bone fractures than men because they have smaller and thinner bones and the bone-protecting hormone estrogen decreases sharply during menopause, according to the Bone Health & Osteoporosis Foundation